IP Library › Granted Patent US 7,135,556
Granted Patent B2
US 7,135,556 · App. 10/736,769 · Granted Nov 14, 2006

NPC1L1 (NPC3) and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,556
App. No.
10/736,769
Granted
Nov 14, 2006
Kind
B2
Abstract

We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels. Also, we claim a composition comprising said polypeptide bound to cholesterol or ezetimibe and a fusion protein comprising the polypeptide thereof.

Claims (13)

1. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4.

2. A polypeptide of claim 1 which is labeled with a member selected from the group consisting of 32 P, 35 S, 3 H, 99m Tc, 123 I, 111 In, 68 Ga, 8 F, 125 I, 131 I, 113m In, 76 Br, 67 Ga, 99m Tc, 123 I, 111 In, and 68 Ga.

3. The polypeptide of claim 1 which is glycosylated.

4. The polypeptide of claim 1 which is capable of binding to cholesterol.

5. A fusion polypeptide comprising the polypeptide of claim 1 fused to another polypeptide.

6. The polypeptide of claim 5 wherein the other polypeptide is selected from the group consisting of a glutathione-s-transferase (GST) tag polypeptide, a hexahistidine tag polypeptide, a maltose binding protein tag, a haemagglutinin polypeptide tag, a cellulose binding protein tag and a myc tag polypeptide.

7. A composition comprising the polypeptide of claim 1 bound to cholesterol.

8. The composition of claim 7 wherein said cholesterol is radiolabled.

9. The composition of claim 8 wherein the radiolabel is 125 I or 3 H.

10. A composition comprising the polypeptide of claim 1 bound to ezetimibe.

11. The composition of claim 10 wherein said ezetimibe is radiolabled.

12. The composition of claim 11 wherein the radiolabel is 125 I or 3 H.

13. The composition of claim 10 wherein the ezetimibe is BODIPY labeled ezetimibe.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →